Fig. 1: Ferric Citrate (FAC) induces ferroptosis in acute myeloid leukemia cells and sensitizes cells to ferrotopsis inducers toxicity.
a Viability curves for the indicated cells at 24 h post treatment. Error bars ± standard deviation. b Half maximal inhibitory concentration percentage (IC50%) of FAC treatment for 24 h across a panel of AML cell lines based on cell viability (n = 3). In our subsequent experiments, we selected two AML cell lines sensitive to FAC in these concentration ranges. c C11-BODIPY staining of MOLM-14 cells treated with increasing doses of FAC + DMSO, FAC + erastine, FAC + Deferoxamine (DFO) or FAC + Ferrostatine-1 (Fer-1). Data are expressed in %positive cells (compared to unstained cells) (n = 3). d Viability curves for MOLM-14 or OCI-AML2 cells treated with FAC and various ferroptosis inducers at 24 h post treatment. Error bars, ± standard deviation. e Viability curves for MOLM-14 or OCI-AML2 cells treated with FAC and various ferroptosis inhibitors at 24 h post treatment. Error bars, ± standard deviation. f Illustrative synergy map of 24 h co-treatment of MOLM-14 cells with FAC and erastin. The mean cell viability of three independent experiments was used (n = 3).
